Cat. No.: HY-15676

Idasanutlin

(Synonyms: RG7388)

52 Cited Publications

고객리뷰

Based on 52 publication(s) in Google Scholar

Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC₅₀ of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.93%
CAS No.: 1229705-06-9
화학식: C₃₁H₂₉Cl₂F₂N₃O₄
분자량:616.48

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Idasanutlin Chemical Structure

CAS No.: 1229705-06-9

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
- Clinical Trial
Chemical Information
Publications (52)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

IC50: 6 nM (p53-MDM2)^[1]

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	0.01 μM Compound: 12, RG7388	Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as growth inhibition by MTT assay Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as growth inhibition by MTT assay	[PMID: 23808545]
MDA-MB-435	IC₅₀	9.1 μM Compound: 12, RG7388	Cytotoxicity against human MDA-MB-435 cells expressing p53 mutant assessed as growth inhibition by MTT assay Cytotoxicity against human MDA-MB-435 cells expressing p53 mutant assessed as growth inhibition by MTT assay	[PMID: 23808545]
RKO	IC₅₀	0.07 μM Compound: 12, RG7388	Cytotoxicity against human RKO cells expressing wild type p53 assessed as growth inhibition by MTT assay Cytotoxicity against human RKO cells expressing wild type p53 assessed as growth inhibition by MTT assay	[PMID: 23808545]
SJSA-1	IC₅₀	0.01 μM Compound: 12, RG7388	Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as growth inhibition by MTT assay Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as growth inhibition by MTT assay	[PMID: 23808545]
SJSA-1	IC₅₀	45 nM Compound: RG7388	Antiproliferative activity against human SJSA1 cells assessed as inhibition of EdU incorporation after 1 hr by Click-iT EdU HCS assay in presence of 10% human serum Antiproliferative activity against human SJSA1 cells assessed as inhibition of EdU incorporation after 1 hr by Click-iT EdU HCS assay in presence of 10% human serum	[PMID: 24456472]
SJSA-1	IC₅₀	45 nM Compound: RG7388	Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 16 hrs by EdU incorporation assay in presence of 10% human serum Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 16 hrs by EdU incorporation assay in presence of 10% human serum	[PMID: 24601644]
SW480	IC₅₀	13.3 μM Compound: 12, RG7388	Cytotoxicity against human SW480 cells expressing p53 mutant assessed as growth inhibition by MTT assay Cytotoxicity against human SW480 cells expressing p53 mutant assessed as growth inhibition by MTT assay	[PMID: 23808545]

In Vitro

Adezmapimod (SB 203580) (HY-10256) (40 μM; 1 h pre-treatment, 6 h treatment) prevents Idasanutlin (60 μM; 6 h)-induced apoptosis and pyroptosis in TP53^mutant NSCLC cell lines HCC827, NCI-H23, PC9, and NCI-H1975, reversing cell death and restoring colony-forming ability^[1].
Idasanutlin (60 μM; 6 h) remodels the tumor microenvironment in TP53mutant NSCLC cell lines HCC827 and PC9 by upregulating immune-related gene expression, increasing pro-inflammatory cytokine secretion, and reducing PD-L1 expression^[1].
Idasanutlin (30-90 nM; 24-72 h) induces p53-dependent growth inhibition, apoptosis, and upregulation of pro-apoptotic p53 target genes BAX and BBC3 in wildtype TP53 MOLT-3 human T-ALL cells, while TP53 knockout MOLT-3 cells are completely resistant^[2].
Idasanutlin (1.5 μM; 24-72 h) induces modest growth inhibition, p53 target gene upregulation, apoptosis, and G₁ cell cycle arrest in wildtype TP53 DFCI12 T-ALL PDX cells^[2].
Idasanutlin (1.5 μM; 16 h) activates the p53 pathway and upregulates p53 target genes in wildtype TP53 DFCI12 T-ALL PDX cells^[2].
Idasanutlin (0.5-5 μM; 8-24 h) increases p53, p21, and (in CT26 cells) MDM2 protein levels in p53^wt B16-F10 and CT26 cells, but not in p53^mut MC38 cells^[3].
Idasanutlin (0.05-5 μM; 8-24 h) dose-dependently activates p53 transcriptional activity, inducing a 2-3-fold luminescence increase in p53^wt B16-F10 and CT26 cells and a 6-fold increase in U-2 OS cells, but has no effect on p53^mut MC38 cells^[3].
Idasanutlin (5 days) reduces cell viability in a p53-dependent manner, with EC₅₀ values of 0.186 μM for B16-F10 cells, 1.492 μM for CT26 cells, 49.665 μM for MC38 cells, and 0.046 μM for U-2 OS cells^[3].
Idasanutlin (0.05-5 μM; 24 h) induces dose-dependent cell cycle arrest in p53wt B16-F10, CT26, and U-2 OS cells, reducing S-phase cell fractions, with a stronger response in U-2 OS cells^[3].
Idasanutlin (0.05-5 μM; 24-72 h) induces dose-dependent caspase 3/7 activation in B16-F10 cells, but does not activate caspase 3/7 in CT26 cells^[3].
Idasanutlin (0.5-2 μM; 5 days) dose-dependently decreases the proliferation of activated human T cells co-cultured with U-2 OS cells^[3].
Idasanutlin (1-40 μM) exhibits no cellular toxicity in HeLa cells at concentrations ≤10 μM^[5].
Idasanutlin (1-40 μM) potently inhibits SFTSV replication in HeLa cells with an IC₅₀ of approximately 5 μM^[5].
Idasanutlin (10 μM) activates p53 and Apaf-1 accumulation, induces apoptosis, and inhibits SFTSV replication in SFTSV-infected HeLa cells, while having no such effects in uninfected HeLa cells^[5].
Idasanutlin (10 nM-1 μM; 72 h) acts as a resensitizing agent for Venetoclax (HY-15531)-resistant KCNR and SJNB12 human neuroblastoma cells, demonstrating greater efficacy in resistant cells under venetoclax pressure than in non-resistant cells^[6].
Idasanutlin (25 nM-400 nM (KCNR); 62.5 nM-1 μM (SJNB12); 15.5 nM-1 μM (FACS); 72 h) induces p21-mediated growth arrest in non-resistant and Venetoclax-resistant KCNR and SJNB12 human neuroblastoma cells, and BAX-mediated apoptosis in Venetoclax-resistant KCNR and SJNB12 human neuroblastoma cells treated with venetoclax^[6].
Idasanutlin (1 nM-100 μM; 24 h-72 h) potently induces dose- and time-dependent cell death in ABC, GCB, Rituximab (HY-P9913)-sensitive, and Rituximab-resistant DLBCL cell lines with 48-hour IC₅₀ values ranging from 0.7 μM to 63.07 μM^[7].
Idasanutlin (1 μM) reduces mitochondrial membrane potential in ABC (TMD8, U2932) and GCB (VAL, OCILy2, DHL4, ROS50) DLBCL cell lines^[7].
Idasanutlin (1 μM; 24 h) decreases MDM2 expression in ABC (TMD8, U2932) and GCB (VAL, OCILy2, DHL4, ROS50) DLBCL cell lines, decreases XIAP expression in VAL and DHL4 GCB DLBCL cell lines, and increases PUMA expression in these DLBCL cell lines^[7].
Idasanutlin (48 h) induces significant apoptosis in high-risk adult ALL patient-derived samples after 48 hours of treatment at respective EC₅₀ concentrations, as shown by increased annexin-V positivity (mean 59.0%) and >3-fold higher cleaved PARP levels^[8].
Idasanutlin (RG7388) potently and selectively inhibits proliferation of wild-type p53 human cancer cell lines (SJSA1, RKO, HCT116) with an average IC₅₀ of 0.03 μM and a selectivity ratio of 344 relative to mutant p53 cell lines (SW480, MDA-MB435)^[10].
Idasanutlin (RG7388) induces dose-dependent p53 stabilization, cell cycle arrest, and apoptosis in wild-type p53 cancer cells via a nongenotoxic p53 activation mechanism^[10].
Idasanutlin (RG7388) (0.5-2 μM; 20 h) activates the p53 pathway in SJSA1 osteosarcoma cells, increasing p53, MDM2, and p21 protein levels after 20 h of incubation at concentrations of 0.5 μM, 1 μM, and 2 μM^[10].
Idasanutlin (0.01-30 μM; 5 days) potently inhibits the viability of p53 wild-type cancer cell lines (including SJSA, RKO, HCT116, H460, A375, SK-MEL-5) with an average IC₉₀ of 300 nM, while showing minimal activity against p53-mutant lines (SW480, MDA435, HeLa)^[11].
Idasanutlin (300 nM-1.8 μM; 16-hour treatment) induces sustained apoptosis in SJSA osteosarcoma cells after a single 16-hour treatment, with 1.8 μM producing a maximal response of 48% annexin V positivity at 48 hours post-washout, eliminating the need for continuous drug exposure^[11].
Idasanutlin (0.3-1.8 μM; 16-hour treatment) activates the p53 pathway in SJSA osteosarcoma cells, with p53 protein remaining elevated for at least 48 hours after a single 16-hour 1.8 μM treatment, supporting sustained antitumor activity without continuous dosing^[11].
Idasanutlin (0.6-2000 nM; 72 h) dose-dependently reduces viability in p53 wild-type MV4-11 (relative IC₅₀ 55 nM), MOLM-13 (relative IC₅₀ 35 nM), and OCI-AML-3 (relative IC₅₀ 164 nM) AML cell lines, but has no effect on p53 mutant HL-60 AML cells^[12].
Idasanutlin (0.6-2000 nM; 72 h) induces apoptosis in a dose-dependent manner in p53 wild-type MV4-11 (relative IC₅₀ 203 nM) and MOLM-13 (relative IC₅₀ 102 nM) AML cell lines, has minimal apoptotic activity in OCI-AML-3 cells, and has no effect on p53 mutant HL-60 AML cells^[12].
Idasanutlin (60 nM; 72 h) induces G1 cell cycle arrest in MV4-11 and MOLM-13 AML cell lines, with apoptosis only evident after cells have gone through at least two cell cycles^[12].
Idasanutlin (100 nM; 6 h) induces significant changes in gene expression in MOLM-13 AML cells, activating the TP53 pathway and inhibiting the CCND1 pathway to drive G1 cell cycle arrest^[12].
Idasanutlin (100 nM; 7-16 h) increases p53 protein levels, induces caspase-3 cleavage (after 16 h), and downregulates Mcl-1 expression over time in MOLM-13 and MV4-11 AML cell lines^[12].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	CL	T_1/2	F	C_max	Bioavailability
Mice^[10]	50 mg/kg	p.o.	/	/	/	9.9 μg/mL	80 %
Mice^[10]	5 mg/kg	i.v.	10.3 mL/min/kg	1.6 h	100 %	/	/

In Vivo

Idasanutlin (40 mg/kg; p.o.; daily on a 5-days-on 2-days-off schedule; 14 days) monotherapy reduces T-ALL burden in 3 of 4 tested PDX xenografts^[2].
Idasanutlin (50-200 mg/kg; p.o.; daily; 14 days) at 50 mg/kg synergizes with anti-PD-1 to significantly reduce CT26 tumor growth in BALB/c mice, while higher doses (100 and 200 mg/kg) fail to control tumor progression and 200 mg/kg reduces circulating T cell numbers^[3].
Idasanutlin (100-200 mg/kg; p.o.; daily; 14 days) at 200 mg/kg combined with anti-PD-1 produces a significant therapeutic effect in the aggressive B16-F10/C57BL/6 melanoma mouse model, while 100 mg/kg idasanutlin alone or combined with anti-PD-1 does not^[3].
Idasanutlin (30 mg/kg; p.o.; days 13-17, 20-24, 27-29) monotherapy induces 56% tumor growth inhibition in female SCID beige mice bearing subcutaneous DoHH-2 DLBCL tumors^[4].
Idasanutlin (80-100 mg/kg; p.o.; days 18-22, 25-36) monotherapy induces 67% tumor growth inhibition in female SCID beige mice bearing subcutaneous Z-138 MCL tumors^[4].
Idasanutlin (10 μmol/L) inhibits SFTSV replication and reduces organoid death in SFTSV-infected mouse liver bile duct organoids^[5].
Idasanutlin (25 mg/kg/day; p.o.; daily; up to three weeks) monotherapy significantly inhibits KCNR neuroblastoma xenograft growth^[6].
Idasanutlin (25 mg/kg/day; p.o.; daily; three weeks) alone or in combination with venetoclax does not significantly inhibit KP-N-YN neuroblastoma xenograft growth due to low BCL-2 dependency and MCL-1-mediated effects^[6].
Idasanutlin (25 mg/kg/day; p.o.; daily; 10 days) monotherapy significantly inhibits CHOA-NBX-4 patient-derived neuroblastoma xenograft growth^[6].
Idasanutlin (12.5-50 mg/kg; p.o.) exhibits potent in vivo efficacy against established SJSA1 osteosarcoma xenografts in nude mice, with 88% tumor growth inhibition at 12.5 mg/kg and greater than 100% tumor growth inhibition at 25 mg/kg^[10].
Idasanutlin (RG7388) (1.11-200 mg/kg; p.o.; daily, once weekly, twice weekly, intermittent, single dose) induces potent, statistically equivalent antitumor activity, apoptosis, and antiproliferation in SJSA osteosarcoma xenografts with both continuous daily dosing (e.g., 30 mg/kg daily producing >100% TGI) and multiple intermittent regimens (e.g., 50 mg/kg twice weekly producing 96% TGI, 80 mg/kg 5 days on/23 days off producing >100% TGI)^[11].
Idasanutlin (30 mg/kg; p.o.; daily; 21 days) induces 30% tumor growth inhibition in female nude mice bearing subcutaneous MV4-11 AML xenografts^[12].
Idasanutlin (30 mg/kg; p.o.; daily; 21 days) increases lifespan by 35% in female NOD/SCID mice bearing orthotopic MV4-11 AML xenografts^[12].
Idasanutlin (30 mg/kg; p.o.; daily; 21 days) increases lifespan by 10% in female NOD/SCID mice bearing orthotopic MOLM-13 AML xenografts^[12].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NSG mice (immunodeficient)^[2]
Dosage:

40 mg/kg
Administration:

p.o.; daily on a 5-days-on 2-days-off schedule; 14 days
Result:

Induced a significant decrease in T-ALL burden in 3 of 4 tested xenografts.
Demonstrated synergistic tumor burden suppression.
Significantly increased overall survival in the combination treatment group compared to single-agent or vehicle controls.

Animal Model:

BALB/c (6- to 10-week-old; syngeneic subcutaneous colorectal carcinoma model via injection of 1×10⁶ CT26 cells into a single flank)^[3]
Dosage:

50 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

p.o.; daily; 14 days
Result:

Slowed tumor growth in 2/8 mice at 50 mg/kg monotherapy.
Significantly reduced tumor size when combined with anti-PD-1 at 50 mg/kg, with only 2/8 mice developing tumors ≥1000 mm³.
Led to 6/8 mice being sacrificed before day 15, with all tumors reaching ≥1000 mm³ at 100 mg/kg monotherapy.
Led to 4/8 mice surviving to day 15, with all tumors reaching ≥1000 mm³ at 200 mg/kg monotherapy.
Caused a significant decrease in the proportion of TCR-positive T cells within the blood lymphocyte population between day 0 and day 7 at 200 mg/kg monotherapy, with the most pronounced decrease when combined with anti-PD-1.
Did not affect PD-1 expression on CD4+ or CD8+ T cells across all doses of monotherapy.
Showed no significant changes in CD69+ and CD25+ T cell populations across all groups.

Animal Model:

C57BL/6 (syngeneic subcutaneous melanoma model via injection of B16-F10 cells into a single flank)^[3]
Dosage:

100 mg/kg; 200 mg/kg
Administration:

p.o.; daily; 14 days
Result:

Provided some tumor growth control at 200 mg/kg monotherapy.
Produced a significant therapeutic effect when combined with anti-PD-1 at 200 mg/kg.
Showed no therapeutic effects at 100 mg/kg alone or combined with anti-PD-1.

Animal Model:

SCID beige (female, bearing established subcutaneous human DoHH-2 tumors)^[4]
Dosage:

30 mg/kg
Administration:

p.o.; days 13-17, 20-24, 27-29
Result:

Achieved 56% tumor growth inhibition (TGI) with a normalized percent tumor control rate (npTCR) of 0.48.

Animal Model:

SCID beige (female, bearing established subcutaneous human Z-138 tumors)^[4]
Dosage:

100 mg/kg (days 18-22); 80 mg/kg (days 25-36)
Administration:

p.o.; days 18-22, 25-36
Result:

Achieved 67% tumor growth inhibition (TGI) with a normalized percent tumor control rate (npTCR) of 0.43.

Animal Model:

NMRI nu^-/nu^- (female, 6-15-weeks-old, 20-30 g, subcutaneous xenograft of BCL-2-dependent, p53 wild-type KCNR neuroblastoma cells)^[6]
Dosage:

25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax)
Administration:

p.o.; daily; up to three weeks
Result:

Resulted in an average tumor volume change of 186% after three weeks, compared with 512% for vehicle control.
In combination with venetoclax, resulted in an average tumor volume change of -80%, with 1/6 complete remissions, 2/6 very good partial responses, and 3/6 partial regressions.
Increased BAX levels in tumors, with more pronounced upregulation in combination-treated tumors.
Mice receiving delayed combination therapy (one week venetoclax monotherapy followed by two weeks combination treatment) showed slightly less favorable responses, with 1 very good partial response, 3 partial regressions, and 3 no responses.

Animal Model:

NMRI nu^-/nu^- (female, 6-15-weeks-old, 20-30 g, subcutaneous xenograft of BCL-2-expressing, p53 wild-type KP-N-YN neuroblastoma cells)^[6]
Dosage:

25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax)
Administration:

p.o.; daily; three weeks
Result:

Resulted in an average tumor volume change of 138% after three weeks, compared with 236% for vehicle control.
In combination with venetoclax, resulted in an average tumor volume change of 97%.
No statistically significant differences in tumor volume change were observed between treatment groups and vehicle control.
BIM was already bound to MCL-1 in untreated xenografts, and complex levels increased upon combination treatment.

Animal Model:

nu^-/nu^- athymic (female, 5-6-weeks-old, 18 g, subcutaneous patient-derived xenograft of BCL-2-dependent CHOA-NBX-4 tumor)^[6]
Dosage:

25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax)
Administration:

p.o.; daily; 10 days
Result:

Resulted in an average tumor volume change of 96% after 10 days, compared with 597% for vehicle control, and led to 1/4 stable disease.
In combination with venetoclax, resulted in an average tumor volume change of -72%, with 5/6 partial regressions.
Upregulated p53, MDM2, and BAX levels, and combination therapy increased cleaved PARP levels, indicating enhanced apoptosis.

Animal Model:

nu^-/nu^- athymic (female, 5-6-weeks-old, 18 g, subcutaneous patient-derived xenograft of BCL-2-dependent, p53 wild-type COG-N-424x tumor)^[6]
Dosage:

25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax)
Administration:

p.o.; daily; 4 days
Result:

Resulted in an average tumor volume change of 185% after 4 days, compared with 216% for vehicle control.
In combination with venetoclax, resulted in an average tumor volume change of 178%.
No statistically significant differences in tumor volume change were observed between treatment groups and vehicle control, and no treatment responses were seen.
Combination therapy led to enhanced PARP cleavage, and idasanutlin treatment upregulated p53 and MDM2 levels.

Animal Model:

Nude mice^[10]
Dosage:

12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration:

p.o.
Result:

Achieved 88% tumor growth inhibition with an AUC of 23 μg·h/mL.
Achieved greater than 100% tumor growth inhibition with an AUC of 29 μg·h/mL.
Resulted in mean tumor volumes near baseline through day 32 post-tumor cell implant.

Animal Model:

Crl:NU-Foxn1nu (female, 10-12 weeks old, implanted with human SJSA osteosarcoma cells)^[11]
Dosage:

1.11 mg/kg; 3.33 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg; 80 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

p.o.; daily (21 days, 28 days, 5 days); once weekly (21 days, 28 days); twice weekly (21 days); 5 days on / 23 days off (28-day cycle); 2 days on / 5 days off (4 cycles over 28 days); single dose
Result:

Achieved 11% tumor growth inhibition (TGI), 0 partial regressions (PR), and 0% increase in lifespan (ILS) at 1.11 mg/kg daily.
Achieved 50% TGI, 0 PR, and 25% ILS at 3.33 mg/kg daily.
Achieved 77% TGI, 1 PR, and 25% ILS at 10 mg/kg daily.
Achieved >100% TGI, 9 PR, and 125% ILS at 30 mg/kg daily for 21 days.
Achieved >100% TGI, 7 PR, and 127% ILS at 30 mg/kg daily for 28 days.
Achieved 79% TGI, 1 PR, and 32% ILS at 50 mg/kg once weekly.
Achieved 96% TGI, 3 PR, and 57% ILS at 50 mg/kg twice weekly.
Achieved >100% TGI, 6 PR, and 127% ILS at 80 mg/kg 5 days on/23 days off.
Achieved >100% TGI, 9 PR, and 188% ILS at 100 mg/kg 2 days on/5 days off.
Achieved >100% TGI, 7 PR, and 162% ILS at 200 mg/kg once weekly (split dose).
Produced statistically significant increase in caspase 3/7 luminescence (max at 48 hours post-dose), increased cleaved PARP-1 (cPARP-1) levels, and reduced Ki-67 positive nuclei at 48 hours post-dose at single 80 mg/kg dose compared to vehicle.
Produced statistically significant increase in caspase 3/7 luminescence (max at 48 hours post-dose), maximal increase in cPARP-1 levels, and maximal reduction in Ki-67 positive nuclei at 48 hours post-dose at single 200 mg/kg dose compared to vehicle.
Produced statistically significant increase in caspase 3/7 luminescence and cPARP-1 levels, plus reduction in Ki-67 positive nuclei, with maximal effects observed on day 3 of dosing at 80 mg/kg daily for 5 days compared to vehicle.
Showed statistical equivalence between 30 mg/kg daily and 50 mg/kg twice weekly; between 50 mg/kg once weekly and 10 mg/kg daily; and between multiple intermittent regimens and 30 mg/kg daily.

Animal Model:

Nude mice (female, 7-week-old) bearing acute myeloid leukemia^[12]
Dosage:

30 mg/kg
Administration:

p.o.; daily; 21 days
Result:

Achieved 30% tumor growth inhibition relative to vehicle control, with a treatment-to-control ratio (TCR) of 0.5 and 95% confidence interval (CI) of 0.26-0.98.

Animal Model:

NOD/SCID mice (female, 10-week-old)^[12]
Dosage:

30 mg/kg
Administration:

p.o.; daily; 21 days
Result:

Resulted in a median survival of 52 days post-inoculation, corresponding to a 35% increase in lifespan (ILS) relative to vehicle control (median survival 38.5 days).\nResulted in a median survival of 23 days post-inoculation, corresponding to a 10% increase in lifespan (ILS) relative to vehicle control (median survival 21 days).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1229705-06-9
Appearance Solid
분자량 616.48
화학식 C₃₁H₂₉Cl₂F₂N₃O₄
Color White to off-white
SMILES

O=C(O)C1=CC(OC)=C(NC([C@H]2[C@H](C3=C(F)C(Cl)=CC=C3)[C@](C4=CC=C(Cl)C=C4F)(C#N)[C@H](CC(C)(C)C)N2)=O)C=C1
Synonyms

RG7388
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (52)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Genet

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. [Abstract]

2025 Jan;57(1):140-153. PMID: 39774325
Cancer Res

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. [Abstract]

2019 May 1;79(9):2404-2414. PMID: 30755442

Idasanutlin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 May 1;79(9):2404-2414. [Abstract]

Immunoblot for p53 pathway responses to 壹dasanutlin treatment (1 μM for 24h) in TTC642 cells reexpressing SMARCB1. Images are representative of three biological replicates.
Cancer Res

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. [Abstract]

2019 Jan 1;79(1):251-262. PMID: 30385614
Nat Commun

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma. [Abstract]

2026 Jun 15. PMID: 42297809
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. [Abstract]

2023 Apr 6;14(1):1941. PMID: 37024504

Idasanutlin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Apr 6;14(1):1941. [Abstract]

Idasanutlin (RG7388; 1, 2.5, 10 μM; 30 min) reverses the Mdm2-induced decreased expression of p53 in H1299 cells.
J Exp Clin Cancer Res

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor. [Abstract]

2021 Aug 12;40(1):255. PMID: 34384466
Adv Sci (Weinh)

CircUGP2 Suppresses Intrahepatic Cholangiocarcinoma Progression via p53 Signaling Through Interacting With PURB to Regulate ADGRB1 Transcription and Sponging miR-3191-5p. [Abstract]

2024 Aug 9:e2402329. PMID: 39120980
Cell Rep Med

A triple-action PROTAC for wild-type p53 cancer therapy. [Abstract]

2025 Dec 16;6(12):102467. PMID: 41308642
Cell Death Differ

QSER1 preserves the suppressive status of the pro-apoptotic genes to prevent apoptosis. [Abstract]

2023 Mar;30(3):779-793. PMID: 36371602
J Control Release

Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy. [Abstract]

2025 Sep 11:387:114225. PMID: 40945534
Cell Death Dis

Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis. [Abstract]

2025 Jun 17;16(1):452. PMID: 40523886
Cancer Lett

FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia. [Abstract]

2025 Jan 3:217446. PMID: 39756787
Cancer Genet

Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells. [Abstract]

2022 Aug:266-267:57-68. PMID: 35785714
Genome Med

The expressed mutational landscape of microsatellite stable colorectal cancers. [Abstract]

2021 Sep 1;13(1):142. PMID: 34470667
Cell Death Discov

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. [Abstract]

2021 May 3;7(1):90. PMID: 33941774
Cell Chem Biol

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. [Abstract]

2021 Jun 17;28(6):855-865.e9. PMID: 33979649
Leukemia

PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. [Abstract]

2022 Feb;36(2):370-382. PMID: 34465864
EMBO J

Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. [Abstract]

2019 Oct 15;38(20):e102096. PMID: 31483066
Haematologica

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. [Abstract]

2018 Nov;103(11):1862-1872. PMID: 29976747
Anal Chem

Combining the NanaPPI Toolbox and AI-Driven Virtual Inhibitor Screening for the p53-MDM2 Interaction. [Abstract]

2025 Jul 29;97(29):15687-15697. PMID: 40624834
Int J Oncol

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. [Abstract]

2022 Mar;60(3):32. PMID: 35179215
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
JCI Insight

TP-0903 is active in models of drug-resistant acute myeloid leukemia. [Abstract]

2020 Dec 3;5(23):e140169. PMID: 33268594
Breast Cancer Res

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. [Abstract]

2021 Mar 4;23(1):29. PMID: 33663585
Cells

PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. [Abstract]

2026 Mar 5;15(5):473. PMID: 41827906
Oncogenesis

LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression. [Abstract]

2022 Jul 2;11(1):37. PMID: 35780125
Cells

Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells. [Abstract]

2018 Dec 22;8(1). pii: E8. PMID: 30583560

Idasanutlin purchased from MedChemExpress. Usage Cited in: Cells. 2018 Dec 22;8(1). pii: E8. [Abstract]

Modulation of apoptosis-related protein expressions in MCF-7 cells after SAHA (7.5 μM), RG7388 (2.0 μM) and SAHA + RG7388 treatment for 24 h.

Idasanutlin purchased from MedChemExpress. Usage Cited in: Cells. 2018 Dec 22;8(1). pii: E8. [Abstract]

Modulation of necroptosis-related protein expressions in MCF-7 cells after (7.5 μM), RG7388 (2.0 μM) and SAHA + RG7388 treatment for 24 h
Colloids Surf B Biointerfaces

Idasanutlin-ionizable lipid nanocomplex for enhanced solubility, stability, and anticancer activity in p53 sensitive lung cancer. [Abstract]

2025 Aug 19;256(Pt 2):115058. PMID: 40848448
Cancer Biol Ther

MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. [Abstract]

2019;20(10):1328-1336. PMID: 31311404
Int J Mol Sci

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer. [Abstract]

2025 Jan 26;26(3):1078. PMID: 39940844
Cancers (Basel)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion. [Abstract]

2022 Dec 21;15(1):29. PMID: 36612026
Cell Signal

KLF11 promotes the proliferation of breast cancer cells by inhibiting p53-MDM2 signaling. [Abstract]

2024 May 27:120:111238. PMID: 38810862
Biomedicines

The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein. [Abstract]

2024 Jun 28;12(7):1449. PMID: 39062022
iScience

Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity. [Abstract]

2024 Apr 9;27(5):109693. PMID: 38689642
Pharm Res

Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. [Abstract]

2021 Jun;38(6):1067-1079. PMID: 34100216
Cancer Res Commun

Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [Abstract]

2026 Mar 1;6(3):616-629. PMID: 41747217
ACS Med Chem Lett

MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3. [Abstract]

2023 Dec 6;15(1):93-98. PMID: 38229760
Sci Pharm

2023 Feb;91(1), 12.

Idasanutlin purchased from MedChemExpress. Usage Cited in: Sci Pharm. 2023 Feb;91(1), 12.

Idasanutlin (1, 10, 30 µM; 24 h) inhibits viability of MCF-7 cells.
Epigenomics

MDM2 and DNMT1 inhibitors induce neuroblastoma cell death through p53-dependent and independent pathways. [Abstract]

2025 Oct;17(15):1057-1068. PMID: 40958635
Medicina (Kaunas)

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells. [Abstract]

2019 Jan 29;55(2):30. PMID: 30700046

Idasanutlin purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2019 Jan 29;55(2):30. [Abstract]

Effect of SAHA and RG7388 treatments on Cell Cycle related Protein levels in MCF-7 cells. Figure shows upregulation of p21, p27, AURKB and CDC25C levels after treatment with 7.5 µM concentration of SAHA and p53 upregulation after RG7388 treatment.
Biochem Bioph Res Co

Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway. [Abstract]

2020 Dec 17;533(4):665-671. PMID: 33051060
Biomed Pharmacother

Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model. [Abstract]

2025 Dec 4:193:118868. PMID: 41349257
bioRxiv

Uncovering senescent fibroblast heterogeneity connects DNA damage response to idiopathic pulmonary fibrosis. [Abstract]

2025 Nov 30:2025.11.26.690792. PMID: 41394576
Preprints

2023 Oct 25.
Preprints

2023 Sep 25, 2023091653.
bioRxiv

2023 Mar 10.
Patent

US20220347186A1.
Patent

US20220340976A1.
Purdue University

2020 May.
Biomedical Journal of Scientific & Technical Research

2019 Jan.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898

용액&용해도

In Vitro:

DMSO : ≥ 45 mg/mL (73.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6221 mL

8.1106 mL

16.2211 mL

5 mM

0.3244 mL

1.6221 mL

3.2442 mL

10 mM

0.1622 mL

0.8111 mL

1.6221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% HPMC/1% Tween-80 in Saline water

Solubility: 10 mg/mL (16.22 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (316 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tang G, et al.. Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis. Cell death & disease. 2025 Jun 17;16(1):452. [Content Brief]

[2]. Johansson KB, et al.. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2023 Dec;37(12):2356-2366. [Content Brief]

[3]. Nieznanska A, et al.. Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Dec;193:118868. [Content Brief]

[4]. Herting F, et al. The triple combination of the CD20 antibody obinutuzumab with the Bcl-2 inhibitor venetoclax (GDC-199) and the MDM2 inhibitor idasanutlin results in superior efficacy and long term response in wildtype p53 NHL tumor models. Blood. 2016 Dec 2;128(22):4178.

[5]. Liu Z, et al.. RG7388 inhibits SFTSV replication by suppressing MDM2-mediated p53 degradation and preventing apoptosome disruption. Science Bulletin. 2025 Jun 21. [Content Brief]

[6]. Vernooij L, et al.. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular cancer therapeutics. 2021 Jun;20(6):1161-1172. [Content Brief]

[7]. Gu JJ, et al.. Targeting MDM2 and XIAP by Idasanutlin in diffuse large B-cell lymphoma. Blood. 2019 Nov 13;134:5301.

[8]. Bell HL, et al. Preclinical investigation of the p53-MDM2 antagonist idasanutlin (RG7388) demonstrates significant activity in high risk adult acute lymphoblastic leukemia. Blood. 2020 Nov 5;136:38.

[9]. Daver NG, et al.. Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study. Blood. 2018 Nov 29;132:767.

[10]. Ding Q, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. Journal of medicinal chemistry. 2013 Jul 25;56(14):5979-83. [Content Brief]

[11]. Higgins B, et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Jul 15;20(14):3742-52. [Content Brief]

[12]. Lehmann C, et al.. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Journal of hematology & oncology. 2016 Jun 28;9(1):50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6221 mL	8.1106 mL	16.2211 mL	40.5528 mL
	5 mM	0.3244 mL	1.6221 mL	3.2442 mL	8.1106 mL
	10 mM	0.1622 mL	0.8111 mL	1.6221 mL	4.0553 mL
	15 mM	0.1081 mL	0.5407 mL	1.0814 mL	2.7035 mL
	20 mM	0.0811 mL	0.4055 mL	0.8111 mL	2.0276 mL
	25 mM	0.0649 mL	0.3244 mL	0.6488 mL	1.6221 mL
	30 mM	0.0541 mL	0.2704 mL	0.5407 mL	1.3518 mL
	40 mM	0.0406 mL	0.2028 mL	0.4055 mL	1.0138 mL
	50 mM	0.0324 mL	0.1622 mL	0.3244 mL	0.8111 mL
	60 mM	0.0270 mL	0.1352 mL	0.2704 mL	0.6759 mL

Idasanutlin

52 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Idasanutlin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Peptidomimetic Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Chemical Probe Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Idasanutlin

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (52)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Idasanutlin Related Classifications

HY-15676 Related Classifications